Medicaid Drug Debate Program
From Wikipedia, the free encyclopedia
The Medicaid Drug Debate Program is a program in the United States that was created by the Omnibus Budget Reconciliation Act of 1990 (OBRA'90). It requires that drug manufacturers have a national rebate agreement with the Secretary of the Department of Health and Human Services (HHS) in order for their state to receive Federal Medicaid coverage of their products. In 2007, 550 pharmaceutics companies participated in the Medicaid Drug Debate Program and 49 states in addition to the District of Columbia supply drugs under the Medicaid Drug Debate Program. In order for manufacturers to be eligible for Medicaid coverage a rebate agreement must be signed with Centers for Medicare and Medicaid Services (CMS).Overview of the Medicaid Drug Rebate Program, U.S. Department of Health & Human Services. Section 606 of the Medicare, Medicaid, SCHIP Balanced Budget Refinement Act of 1999 (BBRA) amended Section 1927(a)(1) allowing states to have the option of different rebate effective dates. This section states that agreements to the debate program that have been entered on or after November 29, 1999 may go into effect that day, and states option, any date after up to the first day of the quarter.History of the Medicaid Drug Rebate Program, U.S. Department of Health & Human Services.
Next Page
This article is based on an article from Wikipedia, the free encyclopedia and is available under the terms of GNU Free Documentation License.
In the Wikipedia there is a list with all authors of this article available.